A phase III trial of neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis.
Sheng Lu, Zhong-Yin Yang, Chao Yan, Wen-Tao Liu, Zhen-Tian Ni, Xue-Xin Yao, Zi-Chen Hua, Run-Hua Feng, Ya-Nan Zheng, Zhen-Qiang Wang, Birendra Kumar Sah, Ming-Min Chen, Zheng-Lun Zhu, Chang-Yu He, Chen Li, Min Yan, Zheng-Gang Zhu
Future Oncol 18(10) 1175-1183
摘要
摘要
Although recent advances in systemic chemotherapy have improved the clinical outcomes of gastric cancer patients with peritoneal metastasis, the peritoneum still represents a common site of treatment failure and disease recurrence. Neoadjuvant intraperitoneal-systemic chemotherapy has been acknowledged as a more aggressive treatment for gastric cancer patients with peritoneal metastasis. In this multicenter phase III randomized controlled trial, 238 patients will be randomly separated into two groups in a 2:1 ratio after laparoscopic exploration. The experimental arm will receive the proposed neoadjuvant intraperitoneal-systemic chemotherapy regimen, whereas the control group will receive a Paclitaxel + S-1 (PS) chemotherapy regimen. The endpoints for the study are overall survival, response rate, gastrectomy radicality rate, progression-free survival and adverse events.
KM 提取结果
0 个 Figure · 0 个 KM 面板